Lupin Secures US FDA Approval for Generic Diabetes Drug

Lupin Gains Key US FDA Approval

Global pharmaceutical company Lupin Limited announced it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. This approval marks a significant step for the Mumbai-based firm, allowing it to market a generic version of the widely used diabetes medication, Xigduo® XR. The approval strengthens Lupin's portfolio in the critical U.S. anti-diabetic market.

Details of the Approval

The FDA's approval covers four different strengths of the combination drug: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. The agency has confirmed that Lupin's product is bioequivalent to the brand-name drug, Xigduo® XR. In addition to the full approvals, Lupin also received tentative approval for a 2.5 mg/1,000 mg dosage. This medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, a condition affecting millions worldwide.

Strategic Expansion in the US Market

The United States represents a crucial market for Lupin, contributing over a third of its global sales. This latest approval reinforces the company's strategy to deepen its presence in high-value therapeutic areas, particularly complex generics. The anti-diabetic segment is a major focus, and adding a generic for a prominent drug like Xigduo® XR enhances Lupin's competitive position and product offerings to American healthcare providers and patients.

A Global Pharmaceutical Player

Headquartered in Mumbai, India, Lupin has a vast operational footprint, with its products distributed in over 100 markets globally. The company's activities are centered around developing and producing branded and generic formulations, active pharmaceutical ingredients (APIs), and biotechnology products. As of March 2022, Lupin operated 15 manufacturing facilities, with 12 located in India and others in the United States, Mexico, and Brazil. The company has established a strong presence in key therapy areas, including respiratory, cardiovascular, anti-infective, and women's health, alongside its growing diabetes franchise.

Strong Financial Performance

This regulatory milestone comes at a time of robust financial health for Lupin. In the second quarter of fiscal year 2025 (July-September), the company reported a consolidated net profit of ₹852.63 crore, a significant 74.1% year-on-year increase. Revenue from operations for the same period grew by 12.6% to ₹5,672.73 crore. This growth was driven by strong performance in both its domestic and international markets.

Broadening the Diabetes Portfolio

The approval for the Xigduo® XR generic is part of a broader push by Lupin to expand its diabetes treatment offerings. The company recently received tentative U.S. FDA approval for Sitagliptin and Metformin Hydrochloride Tablets, a generic version of Janumet®, which had estimated annual U.S. sales of $1.145 billion. It also secured tentative approval for a generic equivalent of Trijardy XR. These developments underscore a clear and focused strategy to become a leading player in the generic diabetes drug market.

Market Reaction and Outlook

Lupin's consistent performance and strategic approvals have been well-received by the market. The company's stock has outperformed the broader market, rising approximately 55% year-to-date, compared to a 9% rise in the BSE Sensex. Following the recent news, Lupin's shares closed at ₹2,294.10 on April 8. With a market capitalization of over ₹93,000 crore, the company continues to demonstrate a solid growth trajectory. Analyst consensus places the average target price for the stock around ₹2,425, suggesting further potential upside.

Conclusion

The U.S. FDA's approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets is a significant achievement for Lupin. It not only allows the company to tap into a lucrative market segment but also aligns perfectly with its long-term strategy of strengthening its complex generics portfolio in the United States. Supported by strong financials and a pipeline of other diabetes drugs, Lupin is well-positioned for continued growth in this key therapeutic area.